Truist Financial
IBB icon

Truist Financial’s iShares Biotechnology ETF IBB Stock Holding History

Truist Financial’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$129M Buy
677,353
+11,010
+2% +$1.89M 0.15% 126
2026
Q1 		$113M Buy
666,343
+24,320
+4% +$4.16M 0.15% 136
2025
Q4 		$108M Buy
642,023
+614,582
+2,240% +$99.8M 0.14% 137
2025
Q3 		$3.96M Sell
27,441
-920
-3% -$126K 0.01% 1002
2025
Q2 		$3.59M Sell
28,361
-17,325
-38% -$2.13M 0.01% 1007
2025
Q1 		$5.84M Sell
45,686
-7,201
-14% -$976K 0.01% 763
2024
Q4 		$6.99M Buy
52,887
+14,770
+39% +$2.08M 0.01% 691
2024
Q3 		$5.55M Buy
38,117
+2,758
+8% +$399K 0.01% 790
2024
Q2 		$4.85M Sell
35,359
-36,325
-51% -$4.85M 0.01% 873
2024
Q1 		$9.84M Buy
71,684
+44,682
+165% +$6.1M 0.01% 632
2023
Q4 		$3.67M Sell
27,002
-11,120
-29% -$1.36M 0.01% 982
2023
Q3 		$4.66M Sell
38,122
-27,146
-42% -$3.45M 0.01% 865
2023
Q2 		$8.29M Sell
65,268
-14,648
-18% -$1.9M 0.01% 650
2023
Q1 		$10.3M Buy
79,916
+5,709
+8% +$747K 0.02% 581
2022
Q4 		$9.74M Buy
74,207
+1,035
+1% +$134K 0.02% 579
2022
Q3 		$8.56M Buy
73,172
+12,890
+21% +$1.6M 0.02% 604
2022
Q2 		$7.09M Sell
60,282
-16,113
-21% -$1.91M 0.01% 691
2022
Q1 		$9.95M Sell
76,395
-24,503
-24% -$3.19M 0.02% 636
2021
Q4 		$15.4M Buy
100,898
+4,128
+4% +$639K 0.02% 509
2021
Q3 		$15.6M Buy
96,770
+2,494
+3% +$420K 0.03% 486
2021
Q2 		$15.4M Buy
94,276
+5,308
+6% +$818K 0.03% 501
2021
Q1 		$13.4M Buy
88,968
+197
+0.2% +$31.3K 0.02% 524
2020
Q4 		$13.4M Buy
88,771
+8,766
+11% +$1.25M 0.03% 517
2020
Q3 		$10.8M Buy
80,005
+8,004
+11% +$1.09M 0.02% 527
2020
Q2 		$9.84M Buy
72,001
+26,338
+58% +$3.36M 0.02% 533
2020
Q1 		$4.92M Sell
45,663
-23,994
-34% -$2.76M 0.01% 684
2019
Q4 		$8.39M Buy
+69,657
New +$7.77M 0.02% 621
2018
Q4 		– Sell
-2,571
Closed -$314K – 771
2018
Q3 		$314K Buy
2,571
+508
+25% +$59.8K 0.01% 673
2018
Q2 		$226K Buy
+2,063
New +$221K ﹤0.01% 716

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Truist Financial's IBB Position: Q2 2026 in Review

Truist Financial increased its iShares Biotechnology ETF (IBB) stake by 1.7% in Q2 2026, buying an estimated $1.89M and bringing the position to 677,353 shares worth $129M. The position accounts for 0.15% of the portfolio, ranked #126.

Truist Financial first reported a position in IBB in Q2 2018 and has held it in 29 quarters since. 956 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • Truist Financial held 677,353 shares of iShares Biotechnology ETF worth $129M as of Q2 2026.
  • Truist Financial bought 11,010 iShares Biotechnology ETF shares in Q2 2026, an estimated $1.89M.
  • iShares Biotechnology ETF made up 0.15% of Truist Financial's portfolio in Q2 2026, its #126 holding.
  • Truist Financial first reported a position in iShares Biotechnology ETF in Q2 2018 and has held it in 29 quarters since.
  • 956 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Truist Financial's 13F filing for Q2 2026, filed 28 Jul 2026.